Takashita Emi, etc.,al. Baloxavir susceptibility of seasonal influenza viruses during the first seven seasons of clinical use in Japan, 2017/18 to 2023/24. Euro Surveill. 2026;31(1):pii=2500336
Baloxavir marboxil, a cap-dependent endonuclease inhibitor, was approved in Japan on 23 February 2018 for the treatment of influenza A and B virus infections, making Japan the first country to authorise its clinical use. On 27 November 2020, its indication was expanded to include prophylactic use for household members or cohabitants of influenza patients who are at high risk of severe disease. For patients aged?≥?12 years, the approved dose is 80 mg for those weighing?>?80 kg, and 40 mg for those weighing?≤?80 kg. For patients aged?12 years, the approved therapeutic doses are 40 mg for those weighing?≥?40 kg, 20 mg for those weighing 20 to?40 kg, and 10 mg for those weighing 10 to?20 kg. Prophylactic use is not approved for people in the 10 to?20 kg weight group.
See Also:
Latest articles in those days:
- The evolution and transmission dynamics of H3N2 influenza virus identified in a respiratory disease outbreak in companion dogs in Alabama, USA 6 hours ago
- Structural and functional characterization of hemagglutinin E190D and Q226H minor variants in human H5N1 A/British Columbia/PHL-2032/2024 6 hours ago
- Spatial risk factors associated with outbreaks of highly pathogenic avian influenza in Pennsylvania’s commercial poultry farms 6 hours ago
- [preprint]H9N2 avian influenza virus in Bangladesh: three genetically distinct co-circulating subgroups retain a largely conserved antigenic phenotype 6 hours ago
- [preprint]Endogenous serine proteases in MDCK sublines support trypsin-independent influenza A virus replication 6 hours ago
[Go Top] [Close Window]


